(MedPage Today) — A lower dose of the CDK4/6 inhibitor ribociclib (Kisqali) managed toxicity without compromising efficacy for women with hormone receptor (HR)-positive/HER2-negative breast cancer, according to results from two studies.
A phase…
Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/117649
Author :
Publish date : 2025-09-25 21:01:00
Copyright for syndicated content belongs to the linked Source.
